Microbot Medical Inc. - Form 8-K Filing Regarding At-the-Market Offering

This Form 8-K filing by Microbot Medical Inc. announces the details of their At-the-Market (ATM) Offering program. The company has an existing Sales Agreement with H.C. Wainwright & Co., LLC, originally dated June 10, 2021, and amended on July 1, 2024. Through this agreement, Microbot Medical Inc. can sell its common stock, with a par value of $0.01 per share, up to an aggregate offering price of $39,230,691. These sales, referred to as "ATM Shares," will be conducted as "at the market offerings" as defined by Rule 415 of the Securities Act of 1933. The sales can occur on the Nasdaq Capital Market, through market makers, directly to the underwriter, or via other legally permissible methods. The company will file a prospectus supplement to its Form S-3 shelf registration statement for these offerings. The filing also includes an opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as Exhibit 5.1, confirming the validity of the ATM Shares, and incorporates by reference the Sales Agreement and its amendment as exhibits.